Phibro Animal Health Corp (NASDAQ:PAHC)
| Market Cap | 1.50B-0.3% |
| Revenue (ttm) | 1.52B+17.1% |
| Net Income | 99.72M+106.6% |
| EPS | 2.44+106.8% |
| Shares Out | 40.54M |
| PE Ratio | 15.04 |
| Forward PE | 9.63 |
| Dividend | $0.48(1.30%) |
| Ex-Dividend Date | Sep 2, 2026 |
| Volume | 5,007 |
| Open | 37.53 |
| Previous Close | 37.72 |
| Day's Range | 36.95 - 37.77 |
| 52-Week Range | 28.25 - 60.08 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 28.00(-24.31%) |
| Earnings Date | Nov 4, 2026 |
Insiders here have filed 14 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About PAHC
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PAHC stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of PAHC by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Michael T. McCaulHouse / R | Sale$1.00K – $15.00K | Sep 1, 2022 |
| Michael T. McCaulHouse / R | Sale$1.00K – $15.00K | Aug 30, 2022 |
| Michael T. McCaulHouse / R | Sale$1.00K – $15.00K | Mar 4, 2022 |
| Michael T. McCaulHouse / R | Sale$1.00K – $15.00K | Mar 2, 2022 |
| Michael T. McCaulHouse / R | Sale$1.00K – $15.00K | Dec 14, 2021 |
| Michael T. McCaulHouse / R | Purchase$1.00K – $15.00K | Mar 4, 2021 |
Recently reported changes in PAHC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PAHC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PAHC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PAHC Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Animal Health | $1.16B | 76.56% |
| Mineral Nutrition | $282.34M | 18.60% |
| Performance Products | $73.53M | 4.84% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-K)
U.S. Patents
New PAHC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PAHC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PAHC
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $47.50M |
| VTIVanguard Morningstar Total Stock Market ETF | $24.89M |
| IWMiShares Russell 2000 ETF | $20.36M |
| VXFVanguard Extended Market ETF | $9.25M |
| IWOiShares Russell 2000 Growth ETF | $7.46M |
| IJTiShares S&P Small-Cap 600 Growth ETF | $7.40M |
Estimated from each fund’s disclosed top holdings × AUM
PAHC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PAHC’s recent data — informational, not investment advice
